Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Oramed Pharmaceuticals Q3 2026 Results: Net Income $18.4M, Down 62.0% YoY

Oramed Pharmaceuticals reported a significant increase in net income to $134.9 million for the nine months ended September 30, 2026, primarily driven by $180.5 million in financial income. The company's total assets grew to $400.9 million, largely due to substantial increases in the fair value of investments and associates.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax28.359.5
Net income18.448.4
EPS (diluted, $ a share)$0.43$1.13

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year-62.0%
Source

10-Q filed with the SEC, NASDAQ: ORMP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Oramed Pharmaceuticals Inc.: key numbers

Share price
$3.90Close, Nov 16
Market cap
$170M
Shares outstanding
43.49MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Oramed Pharmaceuticals Inc.

All →
5:19 PM ET Form 4
Insider Selling

Oramed Pharmaceuticals CFO Avraham Gabay Sells $90.2K of Stock

Avraham Gabay, CFO, sold 20,000 shares of Oramed Pharmaceuticals Inc. at $4.51 a share, worth $90.2K in total on Oct 1, 2026. Shares held after the trade: 861,076 (-2.3%).

Value
$90.2K
Shares
20,000
Price
$4.51
Role
CFO
Holding change
-2.3%
Trade date
Oct 1, 2026
5:19 PM ET Form 4
Insider Selling

Oramed Pharmaceuticals COO & Cbo Joshua Hexter Sells $135K of Stock

Joshua Hexter, COO & Cbo, sold 30,000 shares of Oramed Pharmaceuticals Inc. at $4.51 a share, worth $135K in total on Oct 1, 2026. Shares held after the trade: 1,328,130 (-2.2%).

Value
$135K
Shares
30,000
Price
$4.51
Role
COO & Cbo
Holding change
-2.2%
Trade date
Oct 1, 2026
3:38 PM ET 8-K
Shareholder Meeting

Oramed Pharmaceuticals Shareholder Meeting

Oramed Pharmaceuticals held its 2026 Annual Meeting of Stockholders on September 15, 2026, where shareholders re-elected six directors and ratified Kesselman & Kesselman as the independent auditor. Stockholders also approved an amendment to the 2019 Stock Incentive Plan to increase the authorized share pool by 3,000,000 shares and voted to hold future say-on-pay votes every three years.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.